Efficacy of recombinant human granulocyte colony-stimulating factor in a murine model of pneumococcal pneumonia: Effects of lung inflammation and timing of treatment
F. Dallaire et al., Efficacy of recombinant human granulocyte colony-stimulating factor in a murine model of pneumococcal pneumonia: Effects of lung inflammation and timing of treatment, J INFEC DIS, 183(1), 2001, pp. 70-77
The effect of recombinant human granulocyte colony-stimulating factor (rhG-
CSF) in a murine model of pneumococcal pneumonia was examined. Intranasal i
noculations were 10(7) cfu/mouse (high inoculum) and 5 x 10(4) cfu/mouse (l
ow inoculum) of Streptococcus pneumoniae, which induced severe or mild lung
inflammation, respectively. With the low inoculum, rhG-CSF significantly i
mproved survival when initiated 24 h or 10 min before, but not when initiat
ed 24 h after, infection. Pretreatment with rhG-CSF significantly increased
myeloperoxidase (MPO) activity in lungs 8 h after the infection and increa
sed circulating neutrophil count 24, 48, and 72 h after infection. In contr
ast, rhG-CSF did not improve survival of animals infected with the high ino
culum and did not increase MPO activity or neutrophil count in blood over t
hose of sham-treated controls. These data strongly suggest that the severe
inflammatory response typically observed in pneumococcal pneumonia recruits
a maximum number of neutrophils in the lungs and thus masks the beneficial
effect of rhG-CSF.